Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Panbela Therapeutics (PBLA) and kept the price target at $25.
March 27, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff reaffirms a Buy rating on Panbela Therapeutics with a $25 price target.
The maintenance of a Buy rating and a $25 price target by a Roth MKM analyst suggests a strong confidence in Panbela Therapeutics' future performance. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100